BioSpace News Archive

Axcella Therapeutics reported interim results from their ongoing global Phase 2b randomized, double-blind, placebo-controlled, dose ranging EMMPACT study to evaluate the safety, tolerability, and efficacy of AXA1125 for the treatment of NASH.

MolecuLight Corp. announces it has been awarded a new group purchasing agreement with AllSpire Health GPO, a Mid-Atlantic GPO and a partner of HealthTrust Purchasing Group, engaged with over fifty hospitals in Maryland, New Jersey and Pennsylvania.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that St. Luke’s University Health Network has joined Caris’ Precision Oncology Alliance™.

Ventus Therapeutics, Inc. announced that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.

Indigo Diabetes N.V. today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigo’s continuous multi-metabolite (‘CMM’) device.

Almirall S.A. and Simcere Pharmaceutical Grou announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.

Santhera Pharmaceuticals publishes preliminary financial results for the half-year ended June 30, 2022.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce positive headline results from its ovarian cancer clinical verification study, demonstrating that a Parsortix® blood test can be used to determine if a woman is at risk of a malignant pelvic mass.

Kintor Pharmaceutical Limited announced that the results from a phase Ib study of pruxelutamide for the treatment of patients with androgen receptor positive metastatic breast cancer in China have been published in the international journal, European Journal of Cancer on September 28, 2022, further demonstrating the efficacy and safety of pruxelutamide in patients with AR+ mBC.

Hemogenyx Pharmaceuticals plc, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces its unaudited interim results for the six-month period ended 30 June 2022.